Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-masked comparison of DE-114A ophthalmic solution in allergic conjunctivitis
jRCT2080223524Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of epinastine hydrochloride in allergic conjunctivitis (AC) (3 arms), sponsored by Santen Pharmaceutical. Started May 2017; status: completed.
02
Drugs
epinastine hydrochloride
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on jRCT2080223524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223524.